Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021 07 15; 27(14):4077-4088.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Androstenes
Benzamides
Chromosomal Instability
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplastic Cells, Circulating
Neurosecretory Systems
Nitriles
Phenotype
Phenylthiohydantoin
Prospective Studies
Prostatic Neoplasms, Castration-Resistant
Treatment Outcome

authors with profiles

Russell Z. Szmulewitz